Pasithea Therapeutics
KTTA
8 hedge funds and large institutions have $99.1K invested in Pasithea Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
14% more funds holding
Funds holding: 7 → 8 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
3.16% less ownership
Funds ownership: 6.08% → 2.91% (-3.2%)
59% less capital invested
Capital invested by funds: $243K → $99.1K (-$144K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$95.1K |
| 2 |
Citigroup
New York
|
+$24.3K |
| 3 |
HC
Hurley Capital
New York
|
+$6.55K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$192K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15.1K |
| 3 |
Morgan Stanley
New York
|
-$3.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $66.4K | +$95.1K | +53,547 | New |
|
|
2
Citigroup
New York
| $17.8K | +$24.3K | +13,706 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $5.64K | -$15.1K | -8,531 | -66% |
|
|
HC
4
Hurley Capital
New York
| $4.8K | +$6.55K | +3,689 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $4.25K | +$2.45K | +1,381 | +73% |
|
6
JP Morgan Chase
New York
| $195 | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $10 | – | – | – |
|
|
AC
8
Armistice Capital
New York
| – | -$192K | -61,000 | Closed |
|
|
9
Morgan Stanley
New York
| – | -$3.15K | -1,000 | Closed |
|
KTTA Hedge Fund Activity: Q1 2025 in Review
8 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q1 2025, worth a combined $99.1K — down 59% from $243K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new KTTA positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was AdvisorShares Investments, opening a new position worth an estimated $95.1K. The largest seller was Armistice Capital, exiting entirely with an estimated $192K sold.
- 8 institutional investors held Pasithea Therapeutics (KTTA) as of Q1 2025, up from 7 in Q4 2024.
- Funds reported $99.1K of Pasithea Therapeutics stock for Q1 2025, down 59% quarter-over-quarter.
- 3 funds opened new Pasithea Therapeutics positions in Q1 2025 and 2 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics buyer in Q1 2025 was AdvisorShares Investments, an estimated $95.1K added.
- The largest Pasithea Therapeutics seller in Q1 2025 was Armistice Capital, an estimated $192K sold.
Based on aggregated 13F filings for Q1 2025.